Validation of a hydrophilic interaction ultra‐performance liquid chromatography–tandem mass spectrometry method for the determination of gemcitabine in human plasma with tetrahydrouridine

A simple and reproducible bioanalytical method for the determination of gemcitabine in human plasma treated with tetrahydrouridine (THU) was developed and validated using a hydrophilic interaction ultra‐performance liquid chromatography with tandem mass spectrometry (UPLC‐MS/MS). To prevent deamination of gemcitabine, blood was treated with THU, and the plasma samples obtained after centrifugation were used in this study. Gemcitabine and gemcitabine‐¹³C, ¹⁵N₂ used as an internal standard, were extracted from human plasma treated with THU using a 96‐well Hybrid SPE‐Precipitation plate. Extracts were chromatographed on a hydrophilic interaction chromatography column with isocratic elution. Detection was performed using Quattro Premier with positive electrospray ionization multiple reaction monitoring mode. The standard curve ranged from 10 to 10,000 ng/mL without carryover. No significant interferences were detected in blank plasma and no interferences by 2′‐2′‐difluoro‐2′‐deoxyuridine, a metabolite of gemcitabine. Accuracy and precision in the intra‐batch reproducibility study using quality control samples with three THU levels did not exceed ±5.4 and 7.3%, respectively, and the inter‐batch reproducibility results also met the criteria. Stability of gemcitabine was ensured in whole blood and plasma as well as stability of THU in solutions. The UPLC‐MS/MS method developed was successfully validated and can be applied for gemcitabine bioanalysis in clinical studies. Copyright © 2015 John Wiley & Sons, Ltd.